Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Fluocortolone + lidocaine** is a combination drug comprised of a synthetic corticosteroid (fluocortolone typically as the pivalate and/or caproate ester) and a local amide anesthetic (lidocaine). It is primarily indicated for the local treatment of hemorrhoids and other anorectal inflammatory conditions. Fluocortolone exerts anti-inflammatory, antiallergic, and antipruritic effects through glucocorticoid receptor agonism, thereby reducing swelling, redness, and itching in affected tissues. Lidocaine provides fast-acting, reversible local anesthesia by blocking voltage-gated sodium channels in neuronal cell membranes, which suppresses pain and itching at the site of application. The combination provides both anti-inflammatory and rapid symptomatic relief, and is available as a cream and suppository for rectal and perianal administration. The combination is widely used in Europe, Latin America, and other regions but not approved in the United States.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluocortolone + lidocaine.